UiPath Inc. (NYSE:PATH) Shares Sold by Signaturefd LLC

Signaturefd LLC lessened its stake in shares of UiPath Inc. (NYSE:PATH) by 3.3% in the 4th quarter, Holdings Channel reports. The firm owned 15,369 shares of the healthcare company’s stock after selling 523 shares during the period. Signaturefd LLC’s holdings in UiPath were worth $382,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of PATH. Vanguard Group Inc. grew its stake in UiPath by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock valued at $645,916,000 after acquiring an additional 2,673,718 shares in the last quarter. Glenmede Trust Co. NA grew its stake in UiPath by 3,273.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock valued at $26,777,000 after acquiring an additional 1,518,592 shares in the last quarter. FMR LLC grew its stake in UiPath by 2.9% during the 3rd quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock valued at $277,835,000 after acquiring an additional 463,032 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in UiPath by 179.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 715,688 shares of the healthcare company’s stock valued at $12,245,000 after acquiring an additional 459,965 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in UiPath by 857.7% during the 4th quarter. Federated Hermes Inc. now owns 458,126 shares of the healthcare company’s stock valued at $11,380,000 after acquiring an additional 410,288 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Insider Activity

In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $22.84, for a total value of $365,440.00. Following the sale, the chief financial officer now directly owns 87,505 shares in the company, valued at approximately $1,998,614.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 72,000 shares of company stock worth $1,591,360. 31.03% of the stock is currently owned by corporate insiders.

UiPath Trading Down 1.4 %

Shares of PATH opened at $19.42 on Friday. UiPath Inc. has a twelve month low of $12.38 and a twelve month high of $27.87. The firm’s fifty day simple moving average is $22.30 and its 200-day simple moving average is $21.53. The firm has a market capitalization of $11.05 billion, a price-to-earnings ratio of -114.20 and a beta of 0.96.

UiPath (NYSE:PATH) last announced its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The business had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. On average, analysts predict that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Canaccord Genuity Group upped their price objective on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, March 15th. KeyCorp started coverage on shares of UiPath in a research note on Monday, April 8th. They issued an “overweight” rating and a $27.00 price target for the company. William Blair started coverage on shares of UiPath in a research note on Tuesday, January 2nd. They issued an “outperform” rating for the company. Mizuho increased their price target on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Thursday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of UiPath in a research note on Wednesday, March 20th. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, UiPath currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.41.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.